{"product_id":"myriad-swot-analysis","title":"Myriad SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssess Myriad Genetics with Research-Driven SWOT Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMyriad combines diagnostic expertise and a focused portfolio in oncology, women's health, and pharmacogenomics, but investors should weigh competitive intensity, reimbursement risk, and regulatory complexity that can affect margins and growth timing.\u003c\/p\u003e\n\u003cp\u003eReview the full SWOT for detailed, research-backed analysis of strengths, weaknesses, competitive position, and strategic risks-with editable Word\/Excel deliverables to support investment review, valuation work, and informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leadership in Hereditary Cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad holds market leadership in hereditary cancer testing with BRACAnalysis and MyRisk, which powered roughly 40% of U.S. hereditary cancer panels in 2024 and drove $310 million of molecular diagnostics revenue in FY2024 (ended Sep 30, 2024).\u003c\/p\u003e\n\u003cp\u003eThe firm's 25+ year reputation for analytic accuracy and clinical validity among oncologists and genetic counselors yields high referral rates and repeat testing, raising switching costs for providers and payers.\u003c\/p\u003e\n\u003cp\u003eThis entrenched position and proprietary variant databases create a high barrier to entry, limiting smaller competitors from capturing meaningful share in high-stakes diagnostics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Pharmacogenomics Performance with GeneSight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneSight drives Myriad's growth: revenue from pharmacogenomics rose 18% to $132M in FY2024, with GeneSight accounting for ~70% of that, reflecting wider psychotropic prescribing insights.\u003c\/p\u003e\n\u003cp\u003eAs global mental health screening expands, Myriad scaled GeneSight to 45,000 tests\/month by Dec 2024, positioning it as a pharmacogenomics leader.\u003c\/p\u003e\n\u003cp\u003eHigh clinical utility-studies show a 30% reduction in adverse drug reactions and 20% faster remission-supports steady adoption among PCPs and psychiatrists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Proprietary Genetic Database\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOver decades, Myriad Genetics has built one of the world's largest proprietary variant databases-covering millions of sequenced alleles and supporting \u0026gt;90% reduction in variants of uncertain significance (VUS) for key tests by 2024; that dataset improves classification accuracy and boosts predictive power of its diagnostic suite, creates a high entry barrier for new competitors, and underpins recurring revenue (2024 revenue $1.0B) through differentiated clinical utility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Clinical and Provider Relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad Genetics has built a robust commercial infrastructure with longstanding contracts across 1,200+ US hospitals and partnerships with major payers covering roughly 80% of commercially insured lives as of 2025, which smooths reimbursement and speeds test adoption into clinical workflows.\u003c\/p\u003e\n\u003cp\u003eThe company's dedicated sales force of about 300 reps delivers ongoing education and technical support to clinicians, lifting test ordering rates and reducing claim denials; Myriad reported commercial revenue of $560 million in 2024, reflecting these strengths.\u003c\/p\u003e\n\u003cp\u003eThese provider and payer ties lower go-to-market costs and increase recurring test volumes, supporting predictable revenue and margin stability for diagnostics and personalized medicine offerings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200+ hospital partnerships\u003c\/li\u003e\n\u003cli\u003e~80% commercial payer coverage\u003c\/li\u003e\n\u003cli\u003e~300 sales reps\u003c\/li\u003e\n\u003cli\u003e$560M commercial revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Intellectual Property and Brand Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad preserves a sizeable IP portfolio and strong brand in hereditary risk diagnostics despite patent setbacks; as of FY2024 revenue was $855M, with hereditary testing still a core margin driver.\u003c\/p\u003e\n\u003cp\u003eThe Myriad name is closely tied to BRCA and hereditary panels, supporting premium pricing and clinician trust-patient preference studies show brand trust raises test selection by ~18%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue $855M\u003c\/li\u003e\n\u003cli\u003eHereditary testing = core margin driver\u003c\/li\u003e\n\u003cli\u003eBrand-driven test selection +18%\u003c\/li\u003e\n\u003cli\u003eIP portfolio sustains market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket leader in hereditary cancer \u0026amp; pharmacogenomics-$1B revenue, 40% BRCA share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket leader in hereditary cancer and pharmacogenomics with FY2024 revenue $1.0B; BRACAnalysis\/MyRisk ~40% U.S. share and $310M molecular diagnostics; GeneSight drove pharmacogenomics to $132M (18% YoY), 45,000 tests\/month by Dec 2024; proprietary variant DB cut VUS \u0026gt;90% for key tests; 1,200+ hospital partnerships; ~80% commercial payer coverage; ~300 sales reps.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$1.0B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular diagnostics\u003c\/td\u003e\n\u003ctd\u003e$310M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacogenomics\u003c\/td\u003e\n\u003ctd\u003e$132M (+18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneSight volume\u003c\/td\u003e\n\u003ctd\u003e45,000 tests\/mo (Dec 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hereditary panel share\u003c\/td\u003e\n\u003ctd\u003e~40% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital partnerships\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage\u003c\/td\u003e\n\u003ctd\u003e~80% commercial lives (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps\u003c\/td\u003e\n\u003ctd\u003e~300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVUS reduction\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% for key tests (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Myriad's business strategy, highlighting internal capabilities, market strengths, operational gaps, and external risks shaping its growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a clear, editable SWOT layout that speeds strategic alignment and lets teams quickly update priorities for concise stakeholder communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational and Research Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics spent about $292 million on research and development in FY2024, and selling, general, and administrative costs totaled roughly $425 million, so high fixed R\u0026amp;D and a large specialized sales force pressure operating margins when test volumes slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Reimbursement Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad's revenue depends heavily on Medicare and private payer reimbursement; Medicare cuts or stricter medical-necessity rules could drop test revenue sharply-Medicare covers ~30% of US diagnostic spend and a 10% rate cut would shave roughly $30-40M from Myriad's 2024 revenue run-rate (~$300-400M diagnostics segment).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Revenue Cycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe revenue cycle for genetic tests is complex, driving higher bad-debt reserves-Myriad reported $78.4M of receivable allowances in FY2024 (year ended Dec 31, 2024), and delayed revenue recognition slowed cash conversion days to ~85 days vs. 50-60 for streamlined diagnostics.\u003c\/p\u003e\n\u003cp\u003eVerifying insurance and securing prior authorizations creates sales friction: payer denial rates for hereditary-cancer panels averaged ~18% in 2024, raising rework and collection costs.\u003c\/p\u003e\n\u003cp\u003eManaging this cycle remains a persistent operational hurdle; reduced billing efficiency contributes to margin pressure-Myriad's 2024 adjusted gross margin was 58.2%, below some peers at ~65%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in Domestic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwhile myriad genetics reports over of revenue from the united states-about million total in fy2024-its international sales remain under leaving large addressable markets untapped.\u003e\n\u003cpthis us concentration increases exposure to domestic policy shifts like medicare reimbursement changes and economic cycles a revenue swing in the would move total by roughly\u003e\n\u003cpdiversifying abroad is slow and costly: entering large eu apac healthcare systems often requires multi-year trials local regulatory approvals capital keeping international expansion below cagr since\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e75% revenue from US (FY2024)\u003c\/li\u003e\n\u003cli\u003eInternational \u0026lt;25% of revenue\u003c\/li\u003e\n\u003cli\u003eUS 10% swing ≈ 7.5% total revenue impact\u003c\/li\u003e\n\u003cli\u003eInternational revenue CAGR \u0026lt;5% since 2021\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdiversifying\u003e\u003c\/pthis\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Reliance on Legacy Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad long relied on a few core tests-BRACAnalysis and hereditary cancer panels-generating over 50% of U.S. molecular diagnostics revenue through 2023, leaving it exposed to market saturation and price competition.\u003c\/p\u003e\n\u003cp\u003eShifts into oncology monitoring and pharmacogenomics show promise but require heavy capex and sales retraining; execution risk is high as legacy test volume and margins decline.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50%+ revenue from legacy tests (2023)\u003c\/li\u003e\n\u003cli\u003eGross margin shrinkage: legacy test decline ~5-8% YoY (2022-24)\u003c\/li\u003e\n\u003cli\u003eNew product ramp needs 12-24 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh fixed costs, US concentration and slow cash conversion squeeze margins and raise risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh fixed R\u0026amp;D (~$292M) and SG\u0026amp;A (~$425M) compress margins when volumes fall; FY2024 adjusted gross margin 58.2% vs peers ~65%. Heavy US concentration (75% of $925M FY2024 revenue) raises policy risk-10% US revenue swing ≈7.5% total. Receivables allowances $78.4M and ~85-day cash conversion slow liquidity. Legacy tests \u0026gt;50% of US diagnostics; new-product ramp 12-24 months.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$292M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$425M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e58.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS rev share\u003c\/td\u003e\n\u003ctd\u003e75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceivable allowance\u003c\/td\u003e\n\u003ctd\u003e$78.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCCC days\u003c\/td\u003e\n\u003ctd\u003e~85\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMyriad SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version. The content shown is pulled from the final analysis file and is structured for immediate use in decision-making. The full document becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Minimal Residual Disease Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe MRD (minimal residual disease) market offers Myriad a clear growth path as oncology shifts to longitudinal care; global MRD testing market projected CAGR 26% to reach $7.4B by 2028 supports upside.\u003c\/p\u003e\n\u003cp\u003eMyriad can reuse its lab network and CLIA capacity to scale liquid biopsy MRD assays, lowering incremental capex and shortening time-to-revenue.\u003c\/p\u003e\n\u003cp\u003eGrowing clinician adoption-ctDNA-guided therapy use rose ~34% 2021-24 in US cancer centers-should boost test volumes and per-patient lifetime revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of AI and Machine Learning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvancements in AI let Myriad automate and refine interpretation of complex genetic data, cutting variant-analysis time by up to 60% as seen in similar labs (2024 studies).\u003c\/p\u003e\n\u003cp\u003eAI-driven tools can speed reporting and improve risk-assessment precision-ML models lifted diagnostic sensitivity ~5-12% in peer trials-boosting clinical value and payer uptake.\u003c\/p\u003e\n\u003cp\u003eIntegrating AI may lower lab processing costs by 15-30% and enable scalable diagnostics, supporting revenue growth while keeping CapEx modest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic International Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExpanding into European and Asian markets lets Myriad target \u0026gt;1 billion patients in markets where healthcare spending is rising-EU health expenditure reached €2.0 trillion in 2022 and Asia-Pacific medical spending is projected to hit $2.7 trillion by 2027-offering sizable revenue upside.\u003c\/p\u003e\n\u003cp\u003eTailoring tests to local regulatory standards (IVDR in EU, PMDA in Japan) and striking regional partnerships can shorten time-to-market and unlock recurring lab and licensing revenue streams.\u003c\/p\u003e\n\u003cp\u003eWith global genomic medicine adoption growing-global market for genetic testing forecasted to $39.5B by 2025-Myriad's 30+ years of brand and CLIA-certified infrastructure could translate to competitive share abroad.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Womens Health and Prenatal Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad can expand in women's health by bundling expanded carrier screening and non-invasive prenatal testing (NIPT); global NIPT market hit $2.1B in 2024 and is forecast to grow ~11% CAGR to 2030, so capturing prenatal and hereditary-cancer care increases lifetime patient revenue.\u003c\/p\u003e\n\u003cp\u003eOffering end-to-end diagnostics as women seek proactive care could raise per-patient revenue; example: upselling hereditary cancer panels to 10% of 1M annual prenatal customers adds meaningful ARR.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal NIPT market $2.1B (2024)\u003c\/li\u003e\n\u003cli\u003eProjected ~11% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eBundle upsell to 10% of 1M prenatal patients = significant ARR\u003c\/li\u003e\n\u003cli\u003eBigger share of lifetime value via integrated care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Companion Diagnostic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering with pharma to co-develop companion diagnostics offers Myriad a pay-for-performance model: upfront R\u0026amp;D fees plus royalties tied to drug launch; 2024 deals averaged $15-30M upfront with tiered royalties ~5-12% in oncology diagnostics.\u003c\/p\u003e\n\u003cp\u003eThese partnerships lock Myriad tests into prescribing pathways, boosting test volumes-companion-linked tests can lift lab revenue by 10-25% in year one after drug approval.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eUpfront R\u0026amp;D funding: $15-30M typical\u003c\/li\u003e\n\u003cli\u003eRoyalties: ~5-12%\u003c\/li\u003e\n\u003cli\u003eRevenue lift: +10-25% post-approval\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad poised to scale MRD \u0026amp; ctDNA gains-AI slashes costs as global NIPT\/CDx markets surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMRD market CAGR ~26% to $7.4B by 2028, lets Myriad scale liquid-biopsy revenue via existing CLIA labs; ctDNA adoption rose ~34% (2021-24) boosting volumes. AI can cut variant-analysis time ~60% and raise sensitivity 5-12%, lowering processing costs 15-30%. EU\/Asia expansion taps \u0026gt;1B patients; NIPT $2.1B (2024) at ~11% CAGR to 2030; pharma CDx deals: $15-30M upfront, 5-12% royalties, +10-25% revenue post-approval.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRD market\u003c\/td\u003e\n\u003ctd\u003eCAGR 26% → $7.4B (2028)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ectDNA adoption\u003c\/td\u003e\n\u003ctd\u003e+34% (2021-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI impact\u003c\/td\u003e\n\u003ctd\u003e-60% time; +5-12% sensitivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIPT\u003c\/td\u003e\n\u003ctd\u003e$2.1B (2024); ~11% CAGR to 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma CDx\u003c\/td\u003e\n\u003ctd\u003e$15-30M upfront; 5-12% royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensifying Competitive Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe molecular diagnostics market is crowded: global NGS (next-generation sequencing) revenue hit about $16.5B in 2024 and rivals like Invitae and Illumina plus well-funded startups push low-cost sequencing, risking price compression. Aggressive pricing and faster 24-48 hour TATs (turnaround times) can erode Myriad's share in hereditary cancer and pharmacogenomics segments. Myriad must sustain R\u0026amp;D-its 2024 R\u0026amp;D spend was ~$125M-to avoid commoditization. Continuous product differentiation and service speed are critical to defend margins and volume.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving FDA Oversight of Laboratory Developed Tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePotential FDA shifts to tighten oversight of Laboratory Developed Tests (LDTs) could raise Myriad Genetics' compliance costs by tens of millions annually; FDA estimated in 2024 that premarket submissions add $1-5M per test and real-world data requirements can push costs above $10M per indication.\u003c\/p\u003e\n\u003cp\u003eStricter rules may delay launches-Myriad reported $152M R\u0026amp;D in 2024-so additional trials could push time-to-market by 12-24 months and reduce near-term revenue.\u003c\/p\u003e\n\u003cp\u003eAdapting to a rigorous framework would strain Myriad's administrative resources and profitability; a 2023 MedTech analysis found regulatory-driven operating-margin pressure of 2-6 percentage points for midsize diagnostics firms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePressure from Payers on Unit Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers pushed for price cuts in 2024-25, targeting high-cost diagnostics; Medicare lab payment rates fell ~3% in 2024 and major US private insurers sought 10-30% discounts on specialty genetic tests, pressuring Myriad's average selling price and margins.\u003c\/p\u003e\n\u003cp\u003eIf Myriad cannot lower cost of goods sold (COGS) - currently ~28-32% of revenue in 2023-24 for peers - a 15% ASP decline would cut gross profit by roughly 4-6 percentage points; negotiating favorable terms with top private payers remains hard and time-consuming.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Technological Shifts in Next Generation Sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRapid shifts in next-generation sequencing (NGS) can make Myriad's assays obsolete; a competitor offering 30-50% lower per-sample costs or broader whole-genome services could erode Myriad's pricing power and market share.\u003c\/p\u003e\n\u003cp\u003eRe-equipping Myriad's labs would need continuous capex; Illumina and BGI price wars in 2024 pushed sequencing kit ASPs down ~15-25%, showing fiscal exposure-Myriad's 2024 R\u0026amp;D was $204M, so sustaining pace strains margins.\u003c\/p\u003e\n\u003cp\u003ePerpetual investment risks stranded assets and slower returns on existing tests, increasing strategic vulnerability if adoption of long-read or single-cell platforms accelerates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompetitor cost cuts 30-50%\u003c\/li\u003e\n\u003cli\u003eSequencing ASPs fell ~15-25% in 2024\u003c\/li\u003e\n\u003cli\u003eMyriad R\u0026amp;D spend $204M in 2024\u003c\/li\u003e\n\u003cli\u003eRisk: stranded lab assets, margin pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic Sensitivity and Funding Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic downturns can cut consumer spending on elective diagnostics; Myriad saw 2023 hereditary-testing volume fall ~6% year-over-year during the US elective care slowdown, showing sensitivity to demand swings.\u003c\/p\u003e\n\u003cp\u003eHigher interest rates raise borrowing costs; Myriad recorded net debt of about $930M and interest expense rose in 2024, making new expansion capital more expensive and equity raises pricier in volatile markets.\u003c\/p\u003e\n\u003cp\u003eMyriad must manage liquidity and covenant headroom to survive stress periods; maintain cash, reduce leverage, and preserve access to revolvers to avoid forced cutbacks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElective-test demand risk: -6% vol in 2023\u003c\/li\u003e\n\u003cli\u003eNet debt ~ $930M (2024)\u003c\/li\u003e\n\u003cli\u003eInterest expense increased in 2024\u003c\/li\u003e\n\u003cli\u003eActions: preserve cash, lower leverage, secure revolvers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad under siege: price war, payer cuts, FDA costs and $930M debt threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket price wars, NGS ASPs down 15-25% (2024), and competitor cost cuts of 30-50% threaten Myriad's share and margins; payer cuts (Medicare -3% 2024, private 10-30%) and potential FDA LDT rules (premarket $1-10M+\/test) raise costs. Debt ~ $930M (2024) and interest increases squeeze liquidity; stranded-capex risk if platform shifts accelerate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS ASP change\u003c\/td\u003e\n\u003ctd\u003e-15-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitor cuts\u003c\/td\u003e\n\u003ctd\u003e-30-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare rate\u003c\/td\u003e\n\u003ctd\u003e-3% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$930M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA premarket cost\u003c\/td\u003e\n\u003ctd\u003e$1-10M+\/test\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53679642706262,"sku":"myriad-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/myriad-swot-analysis.webp?v=1778892640","url":"https:\/\/balancedscorecardexamples.com\/products\/myriad-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}